Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.13)
# 2,971
Out of 5,090 analysts
52
Total ratings
30.61%
Success rate
1.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Initiates: Overweight | $18 | $6.84 | +163.35% | 1 | Oct 24, 2025 | |
| ALEC Alector | Downgrades: Neutral | n/a | $1.21 | - | 6 | Oct 22, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $1.87 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $72.73 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $42.61 | +134.69% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $4.34 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $6.78 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.30 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $16.39 | - | 1 | Dec 9, 2024 | |
| ANNX Annexon | Reiterates: Overweight | n/a | $4.52 | - | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.60 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $44.90 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $9.59 | -47.89% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.00 | +550.00% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $20.12 | -60.24% | 1 | Mar 20, 2023 |
Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $6.84
Upside: +163.35%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.21
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.87
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $72.73
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $42.61
Upside: +134.69%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.34
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.78
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.30
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.39
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.52
Upside: -
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.60
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $44.90
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $9.59
Upside: -47.89%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $2.00
Upside: +550.00%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $20.12
Upside: -60.24%